Request for Information for Developing the National Cancer Moonshot Initiative, 29871-29872 [2016-11283]
Download as PDF
<![CDATA[
Federal Register / Vol. 81, No. 93 / Friday, May 13, 2016 / Notices
discrepancy suggests the efficacy of
BPHC’s past investments in FY 2011
and FY 2012 that supported health
centers funded before FY 2012 achieve
patient centered medical home
recognition. The FY 2016 Health Center
Program Patient Centered Medical
Home Supplement is the first funding
not tied to capital improvements that
BPHC has offered to support health
centers’ evolution to patient centered
medical homes since FY 2012.
FOR FURTHER INFORMATION CONTACT:
Olivia Shockey, Expansion Division
Director, Office of Policy and Program
Development, Bureau of Primary Health
Care, Health Resources and Services
Administration at 301–443–9282 or
oshockey@hrsa.gov.
Dated: May 5, 2016.
James Macrae,
Acting Administrator.
[FR Doc. 2016–11413 Filed 5–12–16; 8:45 am]
BILLING CODE 4165–15–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Office of the Secretary
Findings of Research Misconduct
AGENCY:
ACTION:
Office of the Secretary, HHS.
Notice.
Notice is hereby given that
the Office of Research Integrity (ORI)
has taken final action in the following
case:
John G. Pastorino, Ph.D., Rowan
University School of Osteopathic
Medicine: Based on an assessment
conducted by Rowan University School
of Osteopathic Medicine (RUSOM), the
Respondent’s desire to conclude the
matter, and analysis conducted by ORI
in its oversight review, ORI found that
Dr. John G. Pastorino, Associate
Professor, Department of Molecular
Biology, RUSOM, engaged in research
misconduct in research supported by
National Institute on Alcohol Abuse and
Alcoholism (NIAAA), National
Institutes of Health (NIH), grant R01
AA012897 and National Cancer Institute
(NCI), NIH, grant R01 CA118356.
ORI found that Respondent engaged
in research misconduct by intentionally
falsifying and/or fabricating data
reported in the following eight (8)
published papers, one (1) unpublished
manuscript, and one (1) NIH grant
application:
mstockstill on DSK3G9T082PROD with NOTICES
SUMMARY:
• J. Cell. Sci. 123:894–902, 2010
(hereafter referred to as ‘‘J. Cell. Sci.
2010a’’)
VerDate Sep<11>2014
18:05 May 12, 2016
Jkt 238001
• J. Cell. Sci. 123:4117–4127, 2010
(hereafter referred to as ‘‘J. Cell. Sci.
2010b’’)
• J. Cell. Sci. 125:2995–3003, 2012
(hereafter referred to as ‘‘J. Cell. Sci.
2012’’)
• J. Cell. Sci. 126:274–288, 2013
(hereafter referred to as ‘‘J. Cell. Sci.
2013’’)
• J. Cell. Sci. 127:896–907, 2014
(hereafter referred to as ‘‘J. Cell. Sci.
2014’’)
• Biol. Open. 1–11:10;bio.014712, 2015
(hereafter referred to as ‘‘Biol. Open.
2015’’)
• BioChim Biophys Acta. 1827:38–49,
2013 (hereafter referred to as
‘‘BioChim Biophys Acta. 2013’’)
• J. Biol. Chem. 289:26213–26225, 2014
(hereafter referred to as ‘‘J. Biol.
Chem. 2014’’)
• J. Cell. Science, Submitted
manuscript, 2015 (hereafter referred
to as ‘‘J. Cell. Sci. manuscript 2015’’)
• R01 HL132672–01, ‘‘Regulation by
Sirtuin-3 and Mitoneet of the
Permeability Transition Pore in Heart
during Ischemia/Reperfusion Injury,’’
John Pastorino, Ph.D., Principal
Investigator ORI found that Dr.
Pastorino falsified and/or fabricated
Western blot data for mitochondrial
function related to cell/tissue injury,
in fifty-eight (58) blot panels included
in forty-two (42) figures in eight (8)
publications, one (1) unpublished
manuscript, and one (1) grant
application. In the absence of valid
Western blot images, the Respondent
fabricated and/or falsified quantitative
data in associated bar graphs,
statistical analyses presented in figure
legends, and related text.
Specifically, ORI found that
Respondent duplicated images, or
trimmed and/or manipulated blot
images from unrelated sources to
obscure their origin, and relabeled them
to represent different experimental
results in:
• Figures 2A, 2C, 3B, 5A, 7B, and 8A in
J. Cell. Sci. 2010a
• Figures 2B, 5A, 6A, and 6B in J. Cell.
Sci. 2010b
• Figures 1A, 2A, 2B, 4C, 5A, 5B, 6A,
7A, 7B, and 7C in J. Cell. Sci. 2012
• Figures 4F, 5H, and 6A in J. Cell. Sci.
2013
• Figures 1B, 2B, 2C, 3A, 3B, and 4D in
J. Cell. Sci. 2014
• Figures 3A and 6B in Biol. Open 2015
• Figure 2A in BioChim Biophys Acta.
2013
• Figures 1B, 3A, 4D, 5E, and 6C in J.
Biol. Chem. 2014
• Figure 3A in J. Cell. Sci. manuscript
2015
• Figures 3, 8A, 12, and 13A in R01
HL132672–01 NIH grant application
PO 00000
Frm 00040
Fmt 4703
Sfmt 4703
29871
Dr. Pastorino has entered into a
Voluntary Exclusion Agreement
(Agreement) and has voluntarily agreed
for a period of five (5) years, beginning
on April 27, 2016:
(1) To exclude himself from any
contracting or subcontracting with any
agency of the United States Government
and from eligibility or involvement in
nonprocurement programs of the United
States Government referred to as
‘‘covered transactions’’ pursuant to
HHS’ Implementation (2 CFR part 376 et
seq.) of OMB Guidelines to Agencies on
Governmentwide Debarment and
Suspension, 2 CFR part 180 (collectively
the ‘‘Debarment Regulations’’);
(2) that he will neither apply for nor
permit his name to be used on any
application, proposal, or other request
for funds to the United States
Government or any of its agencies, as
defined in the Debarment Regulations;
Respondent will further ensure that
during the period of the voluntary
exclusion, he will neither receive nor be
supported by funds of the United States
Government and its agencies made
available through grants, subgrants,
cooperative agreements, contracts, or
subcontracts, as discussed in the
Debarment Regulations; and
(3) to exclude himself from serving in
any advisory capacity to the U.S. Public
Health Service (PHS) including, but not
limited to, service on any PHS advisory
committee, board, and/or peer review
committee, or as a consultant.
FOR FURTHER INFORMATION CONTACT:
Director, Office of Research Integrity,
1101 Wootton Parkway, Suite 750,
Rockville, MD 20852, (240) 453–8200.
Kathryn Partin,
Director, Office of Research Integrity.
[FR Doc. 2016–11317 Filed 5–12–16; 8:45 am]
BILLING CODE 4150–31–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
Request for Information for Developing
the National Cancer Moonshot
Initiative
This Request for Information
(RFI) describes ways in which the
cancer research community and public
can provide new ideas and comment on
proceedings of the National Cancer
Advisory Board (NCAB) Blue Ribbon
Panel under the umbrella of the
National Cancer Moonshot Initiative.
DATES: Responses should be submitted
to the National Cancer Institute (NCI),
National Institutes of Health (NIH) on or
before 5:00 p.m. EST on July 1, 2016.
SUMMARY:
E:\FR\FM\13MYN1.SGM
13MYN1
29872
Federal Register / Vol. 81, No. 93 / Friday, May 13, 2016 / Notices
Electronic responses are
preferred and should be addressed or
submitted to either: (1) The online
platform, Cancer Research Ideas, at
https://cancerresearchideas.cancer.gov;
or (2) email to cancerresearch@nih.gov.
Non-electronic responses will also be
accepted by calling the NCI Cancer
Information Service at 1–800–422–6237
or by mail to Blue Ribbon Panel,
National Cancer Moonshot Initiative,
National Cancer Institute, 9609 Medical
Center Drive, Bethesda, MD 20892–
9760.
FOR FURTHER INFORMATION: Questions
about this request for information
should be directed to Kelli Marciel,
National Cancer Institute, 9609 Medical
Center Drive, Bethesda, MD 20892–
9760, Kelli.Marciel@nih.gov, 301–594–
3330.
SUPPLEMENTARY INFORMATION: During his
State of the Union address on January
12, 2016, President Barack Obama
announced the establishment of a new
National Cancer Moonshot Initiative to
accelerate cancer research. The
initiative, led by Vice President Joe
Biden, aims to make more therapies
available to more patients, while also
improving our ability to prevent cancer
and detect it at an early stage.
Additional details of the National
Cancer Moonshot Initiative are available
at https://www.cancer.gov/research/keyinitiatives/moonshot-cancer-initiative.
The White House and Vice President
Biden have named a Task Force of 13
heads of federal agencies and offices
who will advise the administration on
research priorities. To ensure that the
National Cancer Moonshot Initiative’s
goals and approaches are grounded in
the best science, President Obama
directed the Moonshot Task Force to
consult with external experts, including
the presidentially appointed National
Cancer Advisory Board (NCAB). A Blue
Ribbon Panel of experts has been
established as a working group of the
NCAB that will assist the board in
providing this advice.
The Blue Ribbon Panel is composed
of leading experts from a broad range of
scientific areas, including biology,
immunology, genomics, diagnostics,
bioinformatics, and cancer prevention
and treatment. Members also include
investigators with expertise in clinical
trials and cancer health disparities. In
addition to researchers, the panel
membership also includes clinicians
and nurses, and representatives of
cancer advocacy organizations and the
pharmaceutical and biotechnology
industries.
The Blue Ribbon Panel will focus on
identifying scientific opportunities in
mstockstill on DSK3G9T082PROD with NOTICES
ADDRESSES:
VerDate Sep<11>2014
18:05 May 12, 2016
Jkt 238001
cancer research that could produce
major advances with additional
emphasis and funding, and propose
ways to overcome barriers to pursuing
these opportunities.
Community input is critical to the
success of the National Cancer
Moonshot Initiative. Indeed, the success
of the initiative will depend on breaking
down silos and encouraging everyone
with an interest in fighting cancer to
work together, share information, and
collaborate on solutions. To enable the
Blue Ribbon Panel to consider a wide
range of input from researchers,
scientists, physicians, advocates,
students, data scientists, and members
of the public, anyone with a scientific
idea or suggestion for addressing cancer
research challenges can contribute by
visiting https://
cancerresearchideas.cancer.gov.
Input is sought in the following areas:
• Expanding clinical trials
• Enhanced data sharing
• Cancer immunology and prevention
• Implementation sciences
• Pediatric cancer
• Precision, prevention and early
detection
• Tumor evolution and progression
This RFI is for planning purposes
only and should not be construed as a
solicitation for applications or
proposals, or as an obligation in any
way on the part of the United States
Federal government. The Federal
government will not pay for the
preparation of any information
submitted or for the government’s use.
Additionally, the government cannot
guarantee the confidentiality of the
information provided.
Dated: May 5, 2016.
Dinah Singer,
Acting Deputy Director, National Cancer
Institute.
[FR Doc. 2016–11283 Filed 5–12–16; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
National Institute on Alcohol Abuse
and Alcoholism; Notice of Closed
Meeting
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended (5 U.S.C. App.), notice is
hereby given of the following meeting.
The meeting will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), title 5 U.S.C.,
as amended. The grant applications and
PO 00000
Frm 00041
Fmt 4703
Sfmt 4703
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the grant
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: National Institute on
Alcohol Abuse and Alcoholism Special
Emphasis Panel; RFA Review and Reverse
Site Visit of INIA NEUROIMMUNE
Consortium.
Date: June 24, 2016.
Time: 8:00 a.m. to 5:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: Marriott New Orleans, 614 Canal
Street, New Orleans, LA 70130.
Contact Person: Beata Buzas, Ph.D.,
Scientific Review Officer, National Institute
on Alcohol Abuse and Alcoholism, National
Institutes of Health, 5635 Fishers Lane, Rm.
2081, Rockville, MD 20852, 301–443–0800,
bbuzas@mail.nih.gov.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.271, Alcohol Research
Career Development Awards for Scientists
and Clinicians; 93.272, Alcohol National
Research Service Awards for Research
Training; 93.273, Alcohol Research Programs;
93.891, Alcohol Research Center Grants;
93.701, ARRA Related Biomedical Research
and Research Support Awards., National
Institutes of Health, HHS)
Dated: May 9, 2016.
Melanie J. Gray,
Program Analyst, Office of Federal Advisory
Committee Policy.
[FR Doc. 2016–11257 Filed 5–12–16; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
National Institute of Diabetes and
Digestive and Kidney Diseases; Notice
of Meetings
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended (5 U.S.C. App.), notice is
hereby given of the following meetings.
The meetings will be open to the
public as indicated below, with
attendance limited to space available.
Individuals who plan to attend and
need special assistance, such as sign
language interpretation or other
reasonable accommodations, should
notify the Contact Person listed below
in advance of the meeting.
The meetings will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The grant applications and
the discussions could disclose
E:\FR\FM\13MYN1.SGM
13MYN1
]]>Agencies
[Federal Register Volume 81, Number 93 (Friday, May 13, 2016)]
[Notices]
[Pages 29871-29872]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2016-11283]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health
Request for Information for Developing the National Cancer
Moonshot Initiative
SUMMARY: This Request for Information (RFI) describes ways in which the
cancer research community and public can provide new ideas and comment
on proceedings of the National Cancer Advisory Board (NCAB) Blue Ribbon
Panel under the umbrella of the National Cancer Moonshot Initiative.
DATES: Responses should be submitted to the National Cancer Institute
(NCI), National Institutes of Health (NIH) on or before 5:00 p.m. EST
on July 1, 2016.
[[Page 29872]]
ADDRESSES: Electronic responses are preferred and should be addressed
or submitted to either: (1) The online platform, Cancer Research Ideas,
at https://cancerresearchideas.cancer.gov; or (2) email to
cancerresearch@nih.gov. Non-electronic responses will also be accepted
by calling the NCI Cancer Information Service at 1-800-422-6237 or by
mail to Blue Ribbon Panel, National Cancer Moonshot Initiative,
National Cancer Institute, 9609 Medical Center Drive, Bethesda, MD
20892-9760.
FOR FURTHER INFORMATION: Questions about this request for information
should be directed to Kelli Marciel, National Cancer Institute, 9609
Medical Center Drive, Bethesda, MD 20892-9760, Kelli.Marciel@nih.gov,
301-594-3330.
SUPPLEMENTARY INFORMATION: During his State of the Union address on
January 12, 2016, President Barack Obama announced the establishment of
a new National Cancer Moonshot Initiative to accelerate cancer
research. The initiative, led by Vice President Joe Biden, aims to make
more therapies available to more patients, while also improving our
ability to prevent cancer and detect it at an early stage. Additional
details of the National Cancer Moonshot Initiative are available at
https://www.cancer.gov/research/key-initiatives/moonshot-cancer-initiative.
The White House and Vice President Biden have named a Task Force of
13 heads of federal agencies and offices who will advise the
administration on research priorities. To ensure that the National
Cancer Moonshot Initiative's goals and approaches are grounded in the
best science, President Obama directed the Moonshot Task Force to
consult with external experts, including the presidentially appointed
National Cancer Advisory Board (NCAB). A Blue Ribbon Panel of experts
has been established as a working group of the NCAB that will assist
the board in providing this advice.
The Blue Ribbon Panel is composed of leading experts from a broad
range of scientific areas, including biology, immunology, genomics,
diagnostics, bioinformatics, and cancer prevention and treatment.
Members also include investigators with expertise in clinical trials
and cancer health disparities. In addition to researchers, the panel
membership also includes clinicians and nurses, and representatives of
cancer advocacy organizations and the pharmaceutical and biotechnology
industries.
The Blue Ribbon Panel will focus on identifying scientific
opportunities in cancer research that could produce major advances with
additional emphasis and funding, and propose ways to overcome barriers
to pursuing these opportunities.
Community input is critical to the success of the National Cancer
Moonshot Initiative. Indeed, the success of the initiative will depend
on breaking down silos and encouraging everyone with an interest in
fighting cancer to work together, share information, and collaborate on
solutions. To enable the Blue Ribbon Panel to consider a wide range of
input from researchers, scientists, physicians, advocates, students,
data scientists, and members of the public, anyone with a scientific
idea or suggestion for addressing cancer research challenges can
contribute by visiting https://cancerresearchideas.cancer.gov.
Input is sought in the following areas:
Expanding clinical trials
Enhanced data sharing
Cancer immunology and prevention
Implementation sciences
Pediatric cancer
Precision, prevention and early detection
Tumor evolution and progression
This RFI is for planning purposes only and should not be construed
as a solicitation for applications or proposals, or as an obligation in
any way on the part of the United States Federal government. The
Federal government will not pay for the preparation of any information
submitted or for the government's use. Additionally, the government
cannot guarantee the confidentiality of the information provided.
Dated: May 5, 2016.
Dinah Singer,
Acting Deputy Director, National Cancer Institute.
[FR Doc. 2016-11283 Filed 5-12-16; 8:45 am]
BILLING CODE 4140-01-P
